BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that it has commenced an investigation on behalf of Prothena Corporation (“Prothena” or the “Company”) (NASDAQ: PRTA) investors concerning the Company and its officers’ possible violations of federal securities laws.
On October 15, 2015, Prothena disclosed its late-stage Phase 2b “PRONTO” study and expansion of its Phase 1/2 clinical trial for the antibody NEOD001. On April 23, 2018, Prothena announced it was ending development of NEOD001 after its Phase 2b PRONTO trial failed to reach either its primary or secondary endpoints. On this news, shares of Prothena fell $25.34, or nearly 69%, to close at $11.50 on April 23, 2018, thereby injuring investors.
If you purchased Prothena securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to email@example.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.